AWM
FATE icon

Avior Wealth Management’s Fate Therapeutics FATE Stock Holding History

Avior Wealth Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17
Closed -$124 – 2749
2024
Q1 		$124 Buy
+17
New +$105 ﹤0.01% 3090
2023
Q1 		– Sell
-6,889
Closed -$69.5K – 1642
2022
Q4 		$69.5K Hold
6,889
– – 0.01% 577
2022
Q3 		$154K Sell
6,889
-2,075
-23% -$60K 0.01% 482
2022
Q2 		$222K Buy
8,964
+1,893
+27% +$52.2K 0.02% 401
2022
Q1 		$274K Buy
+7,071
New +$274K 0.02% 395

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Avior Wealth Management's FATE Position: Q2 2024 in Review

Avior Wealth Management sold out of Fate Therapeutics (FATE) in Q2 2024, closing a stake of 17 shares — an estimated $124 sold.

Avior Wealth Management first reported a position in FATE in Q1 2022 and held it in 5 quarters. The position peaked at $274K in Q1 2022. 182 funds tracked by Wall St. Rank hold FATE as of Q2 2024.

  • Avior Wealth Management reported no remaining Fate Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 17 Fate Therapeutics shares in Q2 2024, an estimated $124.
  • Avior Wealth Management first reported a position in Fate Therapeutics in Q1 2022 and held it in 5 quarters.
  • Avior Wealth Management's Fate Therapeutics position peaked at $274K in Q1 2022.
  • 182 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.